Trastuzumab Emtansine [TRA1]
The treatment of HER2-positive locally advanced/ unresectable or metastatic (Stage IV) breast cancer where all the following criteria are met:
- An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
- Progression of her-2 positive locally advanced or metastatic breast cancer
- Progression during or after the most recent treatment for advanced stage disease or within 6 months of completing treatment for early stage disease
- Previous treatment with a taxane OR capecitabine.
- Previous treatment with trastuzumab
- Perfomance statau of 0, 1 or 2
- Left ventricular ejection fraction of 50% or more
- NOTE: not to be used beyond first disease progression outside the CNS. Do not discontinue if disease progression is within the CNS alone
- No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).
- will otherwise be used as set out in its Summary of Product Characteristics (SPC). Note: To minimise the risk of errors due to the similarity of the product name Trastuzumab Emtansine (Kadcyla) with that of Trastuzumab the recommendations in the Risk Minimisation Plan educational material from the manufacturer should be followed when prescribing, dispensing and administering the product
NHS funded From: 17 October 2017
Additional information
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.